PBF-509
Sponsors
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Conditions
Parkinson Disease
Phase 1
Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy Volunteers
CompletedNCT01691924
Start: 2012-10-31End: 2013-10-31Updated: 2016-03-08
Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy Volunteers
CompletedNCT02111330
Start: 2014-03-31End: 2014-05-31Updated: 2016-03-08